About rozanolixizumab
Neonatal Fc receptor-blocking monoclonal antibody
Used for
- Treats generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive.
Usual adult dose
6 mg/kg subcutaneously once weekly for six weeks if under 50 kg; 7 mg/kg if 50 kg or more. Further courses depend on clinical assessment.
Common side effects
- Headache
- Infections, including respiratory infections
- Diarrhea
- Fever or nausea
Important warnings
- Can increase infection risk; assess for infection before treatment and delay during active infection.
- Vaccinations should be reviewed; avoid live vaccines during treatment.
- May cause hypersensitivity reactions, including serious allergic reactions.
- Safety and effectiveness have not been established in children.
Pregnancy
Human pregnancy data are limited; use only when clearly needed after weighing potential risks.
Breastfeeding
It is unknown whether rozanolixizumab passes into breast milk; consider benefits and potential risks.
Interactions
- May reduce the effectiveness of medicines that bind the neonatal Fc receptor, including some antibody-based treatments.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.